Krebs Biochemicals and Industries share news, announcements and annual reports
NSE: KREBSBIOBSE: 524518Pharmaceuticals & BiotechnologySmall Cap
Krebs Biochemicals and Industries Limited · Formerly Krebs Biochemicals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on NSE, May 2000 on BSE
Last close ₹56.60down ₹1.33 (2.30%)BSE ₹58.36
Share price at the NSE close on 30 Oct 2026. Previous close ₹57.93.
30 Oct: open ₹56.60, high ₹58.49, low ₹56.33
52-week range of traded prices to 30 Oct 2026
₹38.33Low, 30 Mar 2026₹76.85High, 5 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹122 Cr2,740th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Net worth zero or below
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −14.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- Net worth zero or below
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,39760.1% delivered
Krebs Biochemicals and Industries board and management
34 filed, newest first.
Jul 2025
Mar 2025
Feb 2025
4 Feb · Management
Dec 2024
Apr 2024
Jan 2024
Oct 2023
Feb 2023
Nov 2021
Nov 2020
Jun 2020
15 Jun · Management
Apr 2020
Nov 2019
Aug 2019
Feb 2016
Aug 2015
Aug 2014
20 Aug · Management
Following changes have taken place in directorship of the company. 1. P. Nagaraju (Nominee Director of IDBI Bank) - Resigned w.e.f. May 22, 2014. 2. R. Ch Satyanarayana (Small Shareholders Director) - Resigned w.e.f. February 17, 2014. 3. Daya Chandrahas (Nominee Director of Exim Bank) - Resigned w.e.f. December 31, 2013.
May 2013
15 May · Management
Company Secretary of the Company Ms.A.Naga Vasudha has resigned from the office w.e.f. April 10, 2013.
Oct 2010
18 Oct · Management
New Company Secretary Ms. Naga Vasudha appointed by the Board of Directors of the Company will act as Compliance Officer of the Company.
May 2010
24 May · Management
Board of Directors of the company in their meeting held on May 24, 2010 approved and taken a note of the Resignation of Sri. S. Prathap Kumar being Company Secretary and Compliance Officer of the company due to his inability to devote requisite time to the duties of the company due to his personal reasons.24 May · Management
Board of Directors of the company in their meeting held on May 24, 2010 approved and taken a note of the Resignation of Sri. K.S.S. Prasad, Small Share Holder Director due to his inability to devote requisite time to the affairs of the company and to discharge his duties as a Director of the company.
Feb 2010
1 Feb · Management
The Board of Directors of the Company in their meeting held on 27th January, 2010 appointed Mr.A.V.Ravi Kumar S/o Late A.Raghava Rao as Second Nominee Director of Andhra Pradesh Industrial Development Corporation Ltd (APIDC) of the Company. Mr.A.V.Ravi Kumar is a Post Graduate in Commerce and having a qualification of D.P.A. Mr.A.V.Ravi Kumar being an Assistant General Manager of Equity Portfolio of APIDC and he is providing his services to APIDC for the last 27 years. The Co-Option of Mr.A.V.Ravi Kumar as a Director in the Board of Directors of the Company was considered and approved and taken on record by the Board of Directors of the Company at their meeting held on Wednesday 27th January,2010
Aug 2009
6 Aug · Management
Board of Directors appointed Dr. R. T. Ravi Managing Director as their Chairman at their meeting held on July 30, 2009. Now onwards Dr. R. T. Ravi provides his services to the company in the post of Chairman & Managing Director (CMD).
Feb 2009
2 Feb · Management
Board of Directors of the company in their meeting held on January 31, 2009 appointed Mr. Avinash Ravi S/o Dr. R. T. Ravi as Additional Director of the company w.e.f. February 1, 2009. Mr. Avinash Ravi S/o R. T. Ravi was servicing with the company for the last few months in the post of Chief operating Officer. The Board felt that the same person could give much more services to the Board after his appointment as an Additional Director to lead the company in such a way that the company will utilize its optimum capacity and resources. The Same was approved in the board meeting and taken on record by the Board of Directors of the company at their meeting held on January 31, 2009.
Jan 2009
27 Jan · Management
Mr. S. Prathap Kumar being a member of the institute of Company Secretary of India appointed as a company secretary of the company pursuant to section 383A(1) of the Companies Act,1956 read with the Companies ( Appointment and Qualification of Secretary ) Rules, 1988 wef November 01, 2008.
Feb 2007
22 Feb · Management
In the meeting held on 22-2-2007, the board of directors appointed Dr. Naresh Kumar, Senior Vice President, Ranbaxy Laboratories Ltd., as an additional director on the board of M/s Krebs Biochemicals and Industries Ltd.